XenTech is a Patient-Derived Tumor Xenograft platform

Offering preclinical cancer models and services for translational drug development

To foster therapeutic development in oncology, XenTech performs preclinical pharmacology studies using one of the world's largest and best characterized collection of patient-derived tumor xenograft models (PDX) established without intermediary cell culture.

Database access

Search your model into our PDX library

Login :

Password :

> Create an account

Latest news

4-9 December, 2017 | San Antonio | SABC Symposium

  XenTech will attend to the 2017 San Antonio Breast Cancer Symposium. We will talk about state-of-the-art experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease, with international academicians and other private physicians and researchers.   We are looking forward to see you thereĀ !   To know more about SABCS2017, […]

Company

Contract Research Organization

XenTech is primarily a contract research organization (CRO) specializing in preclinical evaluation of novel anti-tumor agents. The company also conducts internal R&D programs....

Partnerships

Research collaborations

XenTech has several research collaborations with pharmaceutical and biotechnology companies and with academic institutions. XenTech has established key collaborations with clinical centers in France...